SAN FRANCISCO (PRWEB) August 23, 2019
MotionHall Inc., the AI-powered marketplace for BioPharma mergers and acquisitions, has announced today it has hired Erin O’Halloran, who formerly held positions at Gilead Sciences, Merck, and Pfizer, as Vice President of Commercial Operations. In her new role, O’Halloran will lead the commercial operations team behind MotionHall, reporting directly to the company’s co-founder and CEO, Rachael Craig.
“O’Halloran’s dedication to our mission of making exploration easier for BioPharma dealmakers, her experience at top pharmaceutical companies, and her background practicing and coaching innovative growth strategies is incredibly valuable in her new role at MotionHall,” said Craig. “She will be building upon a strong foundation of ready-to-scale technology that benefits both companies and patients. I’m delighted to welcome O’Halloran to the team.”
O’Halloran is well-versed in growing enterprise-scale and startup companies. Throughout her career in BioPharma and during her previous role at Gilead Sciences, O’Halloran has advocated for patients’ needs by identifying opportunities in underserved markets and delivering cross-functional strategies to address them. As a trusted advisor to several firms while Principal Consultant for Foster & Spark Consulting, O’Halloran developed, customized, and implemented strategic business solutions for each organization that resulted in measurable successes and increased market-share. As an Instructor at Douglas College, she lent her sales and marketing expertise to guide her students understanding of challenging concepts, consumer behavior, and problem-solving with critical-thinking and practicality. While at Merck, and later Pfizer, she worked directly with Academic Leaders, Medical Residents, and Fellows to support and educate them on anti-infective medications. O’Halloran volunteered as a Board Director for the Royal Columbian Hospital Foundation for 7 years.
“I am passionate about understanding and connecting organizations, ideas, and solutions, said O’Halloran. “By joining MotionHall, I am now a part of an incredibly brilliant team of driven individuals that accelerate bringing innovations and science to market. This work matters — more than anything — to the patients who benefit from these efforts. MotionHall helps bring the best new therapies and cures to those who need them the most.”
MotionHall’s buy and sell-side technologies help to identify 60-100 times as many deal candidates as traditional approaches with significantly more precision and speed. The marketplace provides biotechs, large pharmaceutical companies, Venture Capitalists, and investment banks with increased research confidence and new ways to collaborate. With this highly-qualified community and talented team, MotionHall is ready to scale to new heights.
- Learn more about MotionHall: https://www.motionhall.com/
- Read MotionHall’s blog: https://www.motionhall.com/blog/
- Follow us on Twitter: https://twitter.com/motionhall
- Connect on LinkedIn: https://www.linkedin.com/company/motion-hall/
About MotionHall, Inc.
MotionHall is a Silicon Valley Artificial Intelligence company. Our predictive software tools help biotech companies target the best partners to get their products to market in the least amount of time. MotionHall is supported by many of the world’s most successful pharma and technology industry veterans, including advisors from Genentech, Veeva, Thomson Reuters Life Sciences, and Palantir. We are backed by First Star Ventures and Village Global, a catalyst fund backed by Bill Gates, Michael Bloomberg, and Jeff Bezos.